Millennium Predictive's Outcome
Millennium Pharmaceuticals' new collaboration with Roche Diagnostics to develop prognostic and therapeutic information products in rheumatoid arthritis is notable as being only the second molecular diagnostics discovery deal involving the delivery of targets to a large diagnostics company (the first being Millennium's Becton Dickinson deal in cancer). But the news behind the scenes is that Millennium has also quietly re-integrated two of the three programs in its Predictive Medicine subsidiary, setting the stage for the roll-out of a major, web-based personalized medical information play, most likely by year-end.
You may also be interested in...
Until now, large diagnostics companies have been slow to get involved in the industry's biggest paradigm shift in a decade: the move to molecular markers that will help make diagnostics part of the treatment process. At this year's AACC, the small companies leading the way in this field were beginning to make their presence felt. And the big companies, J&J, Roche, Abbott, Beckman, were starting to talk about their own programs in the field. But they're moving slowly in a fast-moving field, and thus are vulnerable to new competitors.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."